Effect of Helicobacter pylori Treatment on Long-term Mortality in Patients with Hypertension
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background/Aims: A meta-analysis of randomized trials performed in healthy asymptomatic individuals suggested that overall mortality may increase after Helicobacter pylori eradication despite a significant decrease in the gastric cancer incidence and mortality rates. This retrospective population-based cohort study investigated if H. pylori treatment is associated with an increase in overall mortality in patients with hypertension. Methods: From the database of the Korean National Health Insurance Sample Cohort, we selected 198,487 patients treated for hypertension between 2002 and 2010. Those who received H. pylori treatment (H. pylori treatment cohort, 5,541 patients) were matched to those who did not (nontreatment cohort, 11,082 patients) at the ratio of 1 to 2. The primary outcome was the risk of overall mortality. The secondary outcomes were the risks of mortality due to cardiovascular disease, cerebrovascular disease, and cancer. The outcomes were evaluated from 6 months after H. pylori treatment to December 2013. A Cox proportional hazard model was used to estimate the hazard ratios (HRs). Results: During a median follow-up period of 4.8 years, death from any cause was reported in 4.1% of the patients in the H. pylori treatment cohort and 5.5% of the patients in the nontreatment cohort. The adjusted HR (aHR) for overall mortality in the H. pylori treatment cohort was 0.70 (95% confidence interval [CI], 0.60 to 0.82; p<0.001). With regard to cause-specific mortality, compared with the nontreatment cohort, the H. pylori treatment cohort had a lower risk of mortality due to cerebrovascular disease (aHR, 0.46; 95% CI, 0.26 to 0.81; p=0.007). The risks of mortality due to cancer and cardiovascular disease were not different between the cohorts. Conclusions: H. pylori treatment is not associated with an increase in overall mortality in patients treated for hypertension.
Abstract
Background/Aims: A meta-analysis of randomized trials performed in healthy asymptomatic individuals suggested that overall mortality may increase after Helicobacter pylori eradication despite a significant decrease in the gastric cancer incidence and mortality rates. This retrospective population-based cohort study investigated if H. pylori treatment is associated with an increase in overall mortality in patients with hypertension. Methods: From the database of the Korean National Health Insurance Sample Cohort, we selected 198,487 patients treated for hypertension between 2002 and 2010. Those who received H. pylori treatment (H. pylori treatment cohort, 5,541 patients) were matched to those who did not (nontreatment cohort, 11,082 patients) at the ratio of 1 to 2. The primary outcome was the risk of overall mortality. The secondary outcomes were the risks of mortality due to cardiovascular disease, cerebrovascular disease, and cancer. The outcomes were evaluated from 6 months after H. pylori treatment to December 2013. A Cox proportional hazard model was used to estimate the hazard ratios (HRs). Results: During a median follow-up period of 4.8 years, death from any cause was reported in 4.1% of the patients in the H. pylori treatment cohort and 5.5% of the patients in the nontreatment cohort. The adjusted HR (aHR) for overall mortality in the H. pylori treatment cohort was 0.70 (95% confidence interval [CI], 0.60 to 0.82; p<0.001). With regard to cause-specific mortality, compared with the nontreatment cohort, the H. pylori treatment cohort had a lower risk of mortality due to cerebrovascular disease (aHR, 0.46; 95% CI, 0.26 to 0.81; p=0.007). The risks of mortality due to cancer and cardiovascular disease were not different between the cohorts. Conclusions: H. pylori treatment is not associated with an increase in overall mortality in patients treated for hypertension.
참고문헌 (31)
- IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, "IARC Monogr Eval Carcinog Risks Hum, 61", pp.1~241 (1994)
- Ford AC, "Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals : systematic review and meta-analysis of randomised controlled trials", BMJ, 348, pp.g3174~ (2014)
- "Statistics for cause of death"[URL]
- "The top 10 causes of death" (2018)[URL]
- "China Statistical Yearbook 2016"[URL]
- Malfertheiner P, "Management of Helicobacter pylori infection : the Maastricht V", Florence consensus report, 2017, pp.66, 6~30
- Jespersen CM, "Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease : CLARICOR trial", BMJ, 332, pp.22~27 (2006)
- Gluud C, "Clarithromycin for 2 weeks for stable coronary heart disease : 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease", Cardiology, 111, pp.280~287 (2008)
- Cheng YJ, "The role of macrolide antibiotics in increasing cardiovascular risk", J Am Coll Cardiol, 66, pp.2173~2184 (2015)
- Dzutsev A, "The role of the microbiota in inflammation, carcinogenesis, and cancer therapy", Eur J Immunol, 45, pp.17~31 (2015)
- Roy S, "Microbiota : a key orchestrator of cancer therapy", Nat Rev Cancer, 17, pp.271~285 (2017)
- Boursi B, "Recurrent antibiotic exposure may promote cancer formation : another step in understanding the role of the human microbiota", Eur J Cancer, 51, pp.2655~2664 (2015)
- Taler SJ, "Initial treatment of hypertension", N Engl J Med, 378, pp.636~644 (2018)
- Lee J, "Cohort profile : the National Health Insurance Service-National Sample Cohort(NHIS-NSC), South Korea", Int J Epidemiol, 46, pp.e15~ (2017)
- Lee SS, "Clinical implication of an impaired fasting glucose and prehypertension related to new onset atrial fibrillation in a healthy Asian population without underlying disease : a nationwide cohort study in Korea", Eur Heart J, 38, pp.2599~2607 (2017)
- Kang YM, "Mortality and causes of death in a national sample of type 2 diabetic patients in Korea from 2002 to 2013", Cardiovasc Diabetol, 15, pp.131~ (2016)
- World Health Organization (WHO), "ICD-10: International statistical classification of diseases and related health problems. 10th ed", WHO, ~ (1992)
- Kim SG, "Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition", J Gastroenterol Hepatol, 29, pp.1371~1386 (2014)
- Quan H, "Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries", Am J Epidemiol, 173, pp.676~682 (2011)
- Choi IJ, "Helicobacter pylori therapy for the prevention of metachronous gastric cancer", N Engl J Med, 378, pp.1085~1095 (2018)
- Chey WD, "ACG clinical guideline : treatment of helicobacter pylori infection", Am J Gastroenterol, 112, pp.212~239 (2017)
- Svanström H, "Use of clarithromycin and roxithromycin and risk of cardiac death : cohort study", BMJ, 349, pp.g4930~ (2014)
- Wong AY, "Cardiovascular outcomes associated with use of clarithromycin : population based study", BMJ, 352, pp.h6926~ (2016)
- Winkel P, "Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular morbidity over 10years in the CLARICOR randomised, blinded clinical trial", Int J Cardiol, 182, pp.459~465 (2015)
- Mosholder AD, "Long-term risk of acute myocardial infarction, stroke, and death with outpatient use of clarithromycin : a retrospective cohort study", Am J Epidemiol, 187, pp.786~792 (2018)
- Root AA, "Evaluation of the risk of cardiovascular events with clarithromycin using both propensity score and self-controlled study designs", Br J Clin Pharmacol, 82, pp.512~521 (2016)
- Andersen SS, "Clarithromycin use and risk of death in patients with ischemic heart disease", Cardiology, 116, pp.89~97 (2010)
- Ahn HS, "Korea’s thyroid-cancer"epidemic" : screening and overdiagnosis", N Engl J Med, 371, pp.1765~1767 (2014)
- 신애선, "Increasing Trend of Colorectal Cancer Incidence in Korea, 1999-2009", Cancer Research and Treatment, 44(4), pp.219~226 (2012), 대한암학회[DOI]
- Wang ZW, "Helicobacter pylori infection contributes to high risk of ischemic stroke : evidence from a meta-analysis", J Neurol, 259, pp.2527~2537 (2012)
- Yu M, "Association between Helicobacter pylori infection and stroke : a meta-analysis of prospective observational studies", J Stroke Cerebrovasc Dis, 23, pp.2233~2239 (2014)